(Jacob Bruns, Headline USA) A district judge in the state of Texas could soon issue a ruling that would put a temporary injunction on the use of mifepristone, an infanticide pill, across the nation.
The lawsuit was initially filed by Alliance Defending Freedom against the United States Food and Drug Administration, arguing that it had become politicized in its approval of various drugs, including mifepristone, Breitbart reported.
The ADF lawsuit stated that the FDA “chose politics over science and approved chemical abortion drugs for use in the United States. And it has continued to fail them by repeatedly removing even the most basic precautionary requirements associated with their use.”
The soon-to-come decision will be made by U.S. District Court Judge Matthew Kacsmaryk, a Trump nominee.
According to the Breitbart report, mifepristone messes with the hormones in a woman’s body, causing the baby to be brutally starved and expelled from the womb.
The ruling could be of particular significance because mifepristone is used for over half of all infanticides across the nation.
The lawsuit also notes that the FDA did not follow proper procedures when former President Bill Clinton ordered the legalization of chemical abortions in January of 1993.
The FDA “eliminated all procedural safeguards that would rule out ectopic pregnancies, verify gestational age, identify any contraindications to prescribing mifepristone, or identify potential complications like sepsis and hemorrhage, remaining fetal parts, and others until the patient is at a critical time or it is too late to help the patient.”
As a result, the drug, aside from killing infants, has done untold damage to the bodies of pregnant women.
“Women and girls often suffer unexpected episodes of heavy bleeding or severe pain and must rush to the emergency department of the nearest hospital,” the complaint states.
Pro-infanticide activist Kirsten Moore, director of the EMAA Project, complained that such a ruling would be a major blow to the FDA.
“This would be devastating,” Moore said. “This would be taking an FDA approved drug off the market for no public health reason.”
